FibroBiologics, Inc. 8-K

What Happened

• FibroBiologics, Inc. filed an 8‑K reporting that director Matt Link resigned effective July 2, 2026. On July 8, 2026 the Board appointed Kathleen Rubins, Ph.D., as a Class III director, effective July 8, 2026, to serve until the 2029 annual meeting. Dr. Rubins was also named to the Board’s Audit Committee, Compensation Committee and Governance and Nominating Committee.

Key Details

• Matt Link’s resignation: effective July 2, 2026.
• New director: Kathleen Rubins, Ph.D., appointed effective July 8, 2026 as a Class III director through the 2029 annual meeting.
• Committee roles: Audit Committee, Compensation Committee, Governance & Nominating Committee.
• Background & credentials: Founding Director, Trivedi Institute for Space and Global Biomedicine; Professor of Computational and Systems Biology at University of Pittsburgh; U.S. Army Reserve Innovation Officer (Major/O‑4); NASA astronaut from Aug 2009–July 2025; Ph.D. (Stanford) and B.S. (UCSD).
• Compensation & legal: Dr. Rubins will receive standard non‑employee director compensation per the Company’s policy and has entered into the Company’s standard indemnification agreement. The company reported no related‑party transactions requiring disclosure under Item 404(a).

Why It Matters

• This filing updates investors on a board composition change and committee assignments that affect corporate governance. The addition of Dr. Rubins brings scientific, operational and aerospace medicine experience to the board and places her on key oversight committees (Audit, Compensation, Governance), which could be relevant to oversight of R&D and corporate governance activities. The company confirmed compensation and indemnification are consistent with its standard policies.